CGEN - Compugen - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

59.34M

Cash

101.3M

Avg Qtr Burn

N/A

Short % of Float

2.07%

Insider Ownership

5.38%

Institutional Own.

15.76%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Rilvegostomig (PD-1/TIGIT) Details Cancer, Biliary Tract Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rilvegostomig (PD-1/TIGIT) Details Cancer, Biliary Tract Cancer	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Rilvegostomig (PD-1/TIGIT) Details Non-small cell lung carcinoma, Cancer, Hepatobiliary cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COM701 + Opdivo (nivolumab) +/- BMS-986207 Details Endometrial cancer, Cancer, Ovarian cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COM701 + Opdivo (nivolumab) Details Cancer, Solid tumor/s, Metastatic breast cancer	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COM902 (TIGIT) Details Cancer, Advanced malignancies	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COM701+COM902 +Pembrolizumab Details Cancer, Platinum-resistant ovarian cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COM701+COM902 +Pembrolizumab Details Cancer, Colorectal cancer	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COM503 Details Cancer, Solid tumor/s	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
COM701 (PVRIG) Details Ovarian cancer, Colorectal cancer , Non-small cell lung carcinoma, Breast cancer, Endometrial cancer, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.